A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

被引：0

作者：

Muro, Kei

Kim, Tae Won

Park, Young Suk

Uetake, Hiroyuki

Nishina, Tomohiro

Nozawa, Hiroaki

Matsumoto, Hiroshi

Yamazaki, Kentaro

Han, Sae-Won

Lee, Keun-Wook

Deng, Yanhong

Buyse, Marc E.

Satoh, Taroh

Ryoo, Baek-Yeol

Shen, Lin

Iwasa, Satoru

Morita, Satoshi

Sakamoto, Junichi

Xu, Rui-hua

机构：

[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[4] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan

[5] Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan

[7] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan

[8] Shizuoka Canc Ctr, Shizuoka, Japan

[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp,Canc Res Inst, Seoul 151, South Korea

[10] Seoul Natl Univ, Coll Med, Bundang Hosp, Seoul, South Korea

[11] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[12] Int Inst Drug Dev, Cambridge, MA USA

[13] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan

[14] Beijing Canc Hosp, Beijing, Peoples R China

[15] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan

[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[17] Tokai Cent Hosp, Kakamigahara, Japan

[18] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.tps780

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS780

引用

页数：1

共 50 条

[41] FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802)
Aparicio, Thomas
Linot, Benjamin
Le Malicot, Karine
Bouche, Olivier
Boige, Valerie
Francois, Eric
Ghiringhelli, Francois
Legoux, Jean-Louis
Ben Abdelghani, Meher
Phelip, Jean-Marc
Faroux, Roger
Dahan, Laetitia
Taieb, Julien
Bedenne, Laurent
DIGESTIVE AND LIVER DISEASE, 2015, 47 (04) : 271 - 272
[42] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Hiroshi, Tamagawa
Kentaro, Yamazaki
Koichi, Suyama
Michio, Okabe
Kazuya, Suzuki
Nobuhiko, Seki
Kentaro, Kawakami
Mikio, Sato
Yasuo, Takahashi
Tomonori, Hirashima
Masahide, Ebi
Keisei, Taku
Toshio, Otsuji
Fumio, Tamura
Eiji, Shinozaki
Koji, Nakashima
Kensei, Yamaguchi
Masahiko, Ando
Satoshi, Morita
Narikazu, Boku
Ichinosuke, Hyodo
ANNALS OF ONCOLOGY, 2014, 25
[43] Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
Yamada, Yunami
Matsuhashi, Nobuhisa
Fujii, Hironori
Makiyama, Akitaka
Iihara, Hirotoshi
Takahashi, Takao
Watanabe, Daichi
Kiyama, Shigeru
Kobayashi, Ryo
Suzuki, Akio
Yoshida, Kazuhiro
ANTICANCER RESEARCH, 2021, 41 (01) : 533 - 541
[44] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
[45] A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.
Suenaga, Mitsukuni
Matsusaka, Satoshi
Shinozaki, Eiji
Mizunuma, Nobuyuki
Hatake, Kiyohiko
Yamaguchi, Toshiharu
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[46] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
He, Wen-zhuo
Jiang, Chang
Yi, Jiahong
Xue, Ju
Yin, Zhao-feng
Dong, Wen-jing
Xia, Liang-Ping
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Bendell, J. C.
Tournigand, C.
Bednarczyk, M.
Swieboda-Sadlej, A.
Chung, I.
Barone, C.
Tarazi, J. C.
Rosbrook, B.
Ricart, A. D.
Sobrero, A. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[48] FOLFIRI plus bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
Beretta, Giordano Domenico
Petrelli, Fausto
Stinco, Sergio
Cabiddu, Mary
Ghilardi, Mara
Squadroni, Michela
Borgonovo, Karen
Barni, Sandro
MEDICAL ONCOLOGY, 2013, 30 (01)
[49] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
Yong Sang Hong
Jeeyun Lee
Kyu-pyo Kim
Jae-Lyun Lee
Young Suk Park
Joon Oh Park
Se Hoon Park
Sun Young Kim
Ji Yeon Baek
Jee Hyun Kim
Keun-Wook Lee
Tae-You Kim
Tae Won Kim
Investigational New Drugs, 2013, 31 : 183 - 191
[50] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
Hong, Yong Sang
Lee, Jeeyun
Kim, Kyu-pyo
Lee, Jae-Lyun
Park, Young Suk
Park, Joon Oh
Park, Se Hoon
Kim, Sun Young
Baek, Ji Yeon
Kim, Jee Hyun
Lee, Keun-Wook
Kim, Tae-You
Kim, Tae Won
INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191

← 1 2 3 4 5 →